Acitretin for the treatment of cutaneous T-cell lymphoma

“…Cheeley and colleagues 29 reported a retrospective study on the use of acitretin in 32 patients with MF/SS. There was a 59% overall response rate with 1 patient achieving CR, but the interpretation of these results may be confounded by other concomitant treatments received by the patients.…”

Section: Retinoids In Cutaneous T-cell Lymphomamentioning

confidence: 99%

The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma

Huen

Kim

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Retinoids are natural and synthetic vitamin A analogs with effects on cell proliferation, differentiation, and apoptosis. They have significant activity in hematologic malignancies and have been studied extensively in cutaneous T-cell lymphoma. Retinoids bind to nuclear receptors and exert their effects through moderation of gene expression. Retinoic acid receptor and retinoic X receptor exert regulatory activity in vivo, binding to distinct ligands. Studies investigating systemic retinoids as monotherapy and in combination with other agents active against cutaneous lymphoma are reviewed. Side effects associated with retinoids include teratogenicity, dyslipidemias, and hypothyroidism, which should be carefully monitored in patients receiving treatment.

show abstract

“…Retinoids also affect anti‐cell proliferation and anti‐tumor proliferation. Due to its immunosuppressive effect, retinoids are used for the treatment of mycosis fungoides (MF)/cutaneous T‐cell lymphoma (CTCL) (Cheeley, Sahn, DeLong, et al, ). Currently, there are few reports on the treatment of PC‐ALCL by acitretin.…”

Section: Discussionmentioning

confidence: 99%

Acitretin combined with NB‐UVB in the treatment of cutaneous CD30‐positive anaplastic large cell lymphoma

Liu

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Cutaneous CD30+ lymphoproliferative disorders represent a spectrum of skin lymphatic reticular proliferative diseases, including lymphomatoid papulosis (LYP), primary cutaneous anaplastic large cell lymphoma (PC‐ALCL), and borderline lesions between them. Although they all express CD30 as a phenotypic marker and share overlapping immunophenotypic features, they differ in clinical manifestations, pathological features, treatment, and prognosis. LYP is a kind of benign disease characterized by recurrent papules and nodules, and may spontaneously regress. PC‐ALCL presents with solitary tumor or local grouped nodules characterized by large T‐cells and may completely or partially resolve in fewer than half of cases. We reported a case of patient with clinical manifestation and pathologic features consistent with LYP in its early stages, which later turned into PC‐ALCL. This patient was treated with acitretin combined with NB‐UVB and had an obvious response.

show abstract

Acitretin for the treatment of cutaneous T-cell lymphoma

Cited by 37 publications

References 13 publications

Granulomatous slack skin presenting as diffuse poikiloderma and necrotic ulcers, with features of granulomatous vasculitis and response to oral prednisone, acitretin, and oral psoralen plus ultraviolet light therapy—A case report

Granulomatous slack skin presenting as diffuse poikiloderma and necrotic ulcers, with features of granulomatous vasculitis and response to oral prednisone, acitretin, and oral psoralen plus ultraviolet light therapy—A case report

The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma

Acitretin combined with NB‐UVB in the treatment of cutaneous CD30‐positive anaplastic large cell lymphoma

Contact Info

Product

Resources

About